Cardiovascular Effects of Longer-Term, High-Dose OROS Methylphenidate in Adolescents with ADHD
The short-term and longer-term cardiovascular safety of high daily doses of OROS methylphenidate (MPH) of up to 1.5 mg/kg in 114 adolescents with ADHD is reported from Massachusetts General Hospital, Boston, MA.
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Pediatric Neurology Briefs Publishers,
2009-08-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|